Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001641172-25-019884
Filing Date
2025-07-16
Accepted
2025-07-16 16:05:49
Documents
15
Period of Report
2025-06-27
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-ka.htm   iXBRL 8-K/A 49461
2 EX-10.2 ex10-2.htm EX-10.2 125514
3 ex10-2_001.jpg GRAPHIC 9149
  Complete submission text file 0001641172-25-019884.txt   432217

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE bfri-20250627.xsd EX-101.SCH 3975
5 XBRL DEFINITION FILE bfri-20250627_def.xml EX-101.DEF 26989
6 XBRL LABEL FILE bfri-20250627_lab.xml EX-101.LAB 37209
7 XBRL PRESENTATION FILE bfri-20250627_pre.xml EX-101.PRE 25609
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-ka_htm.xml XML 7511
Mailing Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801
Business Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801 781-245-1325
Biofrontera Inc. (Filer) CIK: 0001858685 (see all company filings)

EIN.: 473765675 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-40943 | Film No.: 251127453
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)